This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Oceana COO selected for PharmaVOICE 100

Oceana Therapeutics has announced that the company’s President & COO, David Tierney, has been featured in PharmaVOICE’s 2011 listing of the 100 Most Inspiring People in the Life Sciences Industry.

Now in its seventh year of publication, this listing pays tribute to 100 life-science professionals selected from thousands of nominees, representing a broad cross section of the industry, including pharmaceutical, biotechnology, device technology, clinical trial, R&D, and many others sectors.

According to Taren Grom, PharmaVOICE’s Editor-in-Chief and cofounder, the PharmaVOICE 100 are individuals who think outside the box, pioneer new paths to success, and who inspire their colleagues in the industry. They are individuals who translate industry issues into opportunities and take the time to mentor the next generation of leaders in the life sciences.

Tierney is a repeat recipient of this honour, having previously been on the 2005 and 2006 lists. More recently, in June of this year, Tierney was also named, along with John T. Spitznagel, Oceana’s Chairman & CEO, as a co-recipient of the Ernst & Young Entrepreneur Of The Year® 2011 award for the New Jersey region Emerging company category.

Prior to Oceana, Tierney served as CEO of Valera Pharmaceuticals, a company he joined in 2002 and transformed from an obscure research firm into a commercial specialty pharma enterprise, which was acquired in 2007 and has since become part of Endo Pharmaceuticals.

Earlier, he collaborated with Spitznagel at Roberts Pharmaceutical, a company they both joined in the late 1990s to successfully salvage that company’s failing operations and dramatically build earnings and asset value, which led to Roberts’ purchase in 1999 by Shire plc. for over $1.2 billion.

“I have known David for more than 15 years and there is no question he is highly deserving of the PharmaVOICE 100 honour,” said Spitznagel.

“David’s abilities as a life-science professional are exceptional and have significantly influenced the dramatic growth of Oceana from a start-up in mid 2008 to a global specialty company today. I am proud to call him a friend as well as a colleague.”

Tierney said: “I am sincerely delighted to be included in the PharmaVOICE 100. This and other honours and awards bestowed upon Oceana and several of our management team in the past couple of years reflect the hard work and support of many talented people who continue to drive the success of our company.”

“It is our team commitment to excellence that has placed Oceana on the threshold of an exciting new growth phase as we prepare for the US launch of Solesta.

“Recently approved by FDA, Solesta is a minimally invasive, out-patient treatment option for faecal incontinence that we believe represents a major advancement in addressing the needs of many underserved patients afflicted with this life-limiting condition.”

Oceana Therapeutics